Cargando…

Long Term Follow-Up of 103 Untreated Adult Patients with Type 1 Gaucher Disease

The introduction of disease-specific therapy for patients with type I Gaucher disease (GD1) was a revolution in the management of patients, but not without cost. Thus, the management of mildly affected patients is still debated. We herein report a long-term follow-up (median (range) of 20 (5–58) yea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dinur, Tama, Zimran, Ari, Becker-Cohen, Michal, Arkadir, David, Cozma, Claudia, Hovakimyan, Marina, Oppermann, Sebastian, Demuth, Laura, Rolfs, Arndt, Revel-Vilk, Shoshana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6832634/ https://www.ncbi.nlm.nih.gov/pubmed/31614613 http://dx.doi.org/10.3390/jcm8101662

Ejemplares similares

Glucosylsphingosine (lyso-Gb1) as a Biomarker for Monitoring Treated and Untreated Children with Gaucher Disease
por: Hurvitz, Noa, et al.
Publicado: (2019)

Impact of Long-Term Enzyme Replacement Therapy on Glucosylsphingosine (Lyso-Gb1) Values in Patients with Type 1 Gaucher Disease: Statistical Models for Comparing Three Enzymatic Formulations
por: Dinur, Tama, et al.
Publicado: (2021)

Contribution of Glucosylsphingosine (Lyso-Gb1) to Treatment Decisions in Patients with Gaucher Disease
por: Dinur, Tama, et al.
Publicado: (2023)

A Comprehensive Assessment of Qualitative and Quantitative Prodromal Parkinsonian Features in Carriers of Gaucher Disease—Identifying Those at the Greatest Risk
por: Becker-Cohen, Michal, et al.
Publicado: (2022)

Real-Life Experience with Oral Eliglustat in Patients with Gaucher Disease Previously Treated with Enzyme Replacement Therapy
por: Istaiti, Majdolen, et al.
Publicado: (2022)

Gaucher Disease Diagnosis Using Lyso-Gb1 on Dry Blood Spot Samples: Time to Change the Paradigm?
por: Dinur, Tama, et al.
Publicado: (2022)

Macular Ganglion Cell Complex and Peripapillary Retinal Nerve Fiber Layer Thinning in Patients with Type-1 Gaucher Disease
por: Weill, Yishay, et al.
Publicado: (2020)

Patient reported outcome measures in a large cohort of patients with type 1 Gaucher disease
por: Dinur, Tama, et al.
Publicado: (2020)

High-Dose Ambroxol Therapy in Type 1 Gaucher Disease Focusing on Patients with Poor Response to Enzyme Replacement Therapy or Substrate Reduction Therapy
por: Istaiti, Majdolen, et al.
Publicado: (2023)

The Bone Biomarker of Quantitative Chemical Shift Imaging in Patients with Type 1 Gaucher Disease Receiving Low-Dose Long-Term Enzyme Replacement Therapy
por: Zimran, Ari, et al.
Publicado: (2023)

The definition of neuronopathic Gaucher disease
por: Schiffmann, Raphael, et al.
Publicado: (2020)

Value of Glucosylsphingosine (Lyso-Gb1) as a Biomarker in Gaucher Disease: A Systematic Literature Review
por: Revel-Vilk, Shoshana, et al.
Publicado: (2020)

Improvement in bone marrow infiltration in patients with type I Gaucher disease treated with taliglucerase alfa
por: Zimran, Ari, et al.
Publicado: (2018)

Simultaneous Bilateral Femoral Osteonecrosis in Gaucher Disease
por: Cohen, Daniel, et al.
Publicado: (2023)

Insights into the Value of Lyso-Gb1 as a Predictive Biomarker in Treatment-Naïve Patients with Gaucher Disease Type 1 in the LYSO-PROOF Study
por: Curado, Filipa, et al.
Publicado: (2023)

Brain-Derived Neurotrophic Factor (BDNF) Is Associated with Platelet Activity and Bleeding Tendency in Patients with Gaucher Disease
por: Azoulay, David, et al.
Publicado: (2022)

Anesthetic Approaches and Perioperative Complications of Total Hip Arthroplasty in Gaucher Disease: A Control-Matched Retrospective-Cohort Study
por: Grass, Ariel, et al.
Publicado: (2023)

Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS)
por: Hughes, Derralynn A., et al.
Publicado: (2022)

Treatment Efficiency in Gaucher Patients Can Reliably Be Monitored by Quantification of Lyso-Gb1 Concentrations in Dried Blood Spots
por: Cozma, Claudia, et al.
Publicado: (2020)

Reply to Mistry et al. The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on “Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158”
por: Hughes, Derralynn A., et al.
Publicado: (2023)

A Deep-Learning Approach to Spleen Volume Estimation in Patients with Gaucher Disease
por: Azuri, Ido, et al.
Publicado: (2023)

Real-World Experiences with Taliglucerase Alfa Home Infusions for Patients with Gaucher Disease: A Global Cohort Study
por: Revel-Vilk, Shoshana, et al.
Publicado: (2023)

Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry
por: Rosenbloom, Barry E., et al.
Publicado: (2022)

P1633: LOW SERUM BDNF LEVELS ARE ASSOCIATED WITH LOWER PLATELETS’ CD62P REACTIVITY AND INCREASED BLEEDING TENDENCY IN PATIENTS WITH GAUCHER DISEASE
por: Azoulay, D., et al.
Publicado: (2022)

A global neuronopathic gaucher disease registry (GARDIAN): a patient-led initiative
por: Collin-Histed, Tanya, et al.
Publicado: (2023)

Dental profile of patients with Gaucher disease
por: Fischman, Stuart L, et al.
Publicado: (2003)

Hepatocellular carcinoma in Gaucher disease: an international case series
por: Regenboog, Martine, et al.
Publicado: (2018)

Review of the safety and efficacy of imiglucerase treatment of Gaucher disease
por: Elstein, Deborah, et al.
Publicado: (2009)

Glucosylsphingosine Is a Highly Sensitive and Specific Biomarker for Primary Diagnostic and Follow-Up Monitoring in Gaucher Disease in a Non-Jewish, Caucasian Cohort of Gaucher Disease Patients
por: Rolfs, Arndt, et al.
Publicado: (2013)

Fertility preservation in young cancer patients
por: Revel, Ariel, et al.
Publicado: (2010)

Genetic characterization of the Albanian Gaucher disease patient population
por: Cullufi, Paskal, et al.
Publicado: (2020)

Patient blood management programs: how to spread the word?
por: Revel-Vilk, Shoshana, et al.
Publicado: (2018)

Pharmacologic properties of high-dose ambroxol in four patients with Gaucher disease and myoclonic epilepsy
por: Kim, Yoon-Myung, et al.
Publicado: (2020)

Characteristics of 26 patients with type 3 Gaucher disease: A descriptive analysis from the Gaucher Outcome Survey
por: Schwartz, Ida Vanessa D., et al.
Publicado: (2017)

Patient centered guidelines for the laboratory diagnosis of Gaucher disease type 1
por: Dardis, A., et al.
Publicado: (2022)

Occurrence of Amyotrophic Lateral Sclerosis in Type 1 Gaucher Disease
por: Oliveira, Lais M., et al.
Publicado: (2021)

Taliglucerase alfa: safety and efficacy across 6 clinical studies in adults and children with Gaucher disease
por: Zimran, Ari, et al.
Publicado: (2018)

Glucosylsphingosine Causes Hematological and Visceral Changes in Mice—Evidence for a Pathophysiological Role in Gaucher Disease
por: Lukas, Jan, et al.
Publicado: (2017)

Poor results of drilling in early stages of juxta-articular osteonecrosis in 12 joints affected by Gaucher disease
por: Lebel, Ehud, et al.
Publicado: (2009)

Demographics and patient characteristics of 1209 patients with Gaucher disease: Descriptive analysis from the Gaucher Outcome Survey (GOS)
por: Zimran, Ari, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_jedmesrilfhphrk0ur3aa8a4ku